



Universiteit  
Leiden  
The Netherlands

## **Design, synthesis, characterization and biological studies of ruthenium and gold compounds with anticancer properties**

Garza-Ortiz, A.

### **Citation**

Garza-Ortiz, A. (2008, November 25). *Design, synthesis, characterization and biological studies of ruthenium and gold compounds with anticancer properties*. Retrieved from <https://hdl.handle.net/1887/13280>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13280>

**Note:** To cite this publication please use the final published version (if applicable).

# Table of Contents

	Page
<b>List of abbreviations</b>	i-ii
<b>List of schematic representation of synthesized compounds</b>	iii-vi
<b>Chapter 1 Design, Synthesis, Characterization and Biological Studies of Ruthenium and Gold Compounds with anticancer properties</b>	1
1.1 Introduction	1
1.2 Cancer and its statistics. Definition and actual trends	2
1.3 Cancer therapeutics	3
1.4 Chemotherapy and metal-based anticancer compounds	4
1.5 Gold compounds as potential anticancer therapeutics	9
1.6 Ruthenium compound as potential anticancer therapeutics	16
1.7 Aim and contents of this thesis	30
1.8 References	31
<b>Chapter 2 Novel Mononuclear Gold(III) Complexes with Modified 2-(arylo)pyridine Ligands: Synthesis and Characterization</b>	39
2.1 Introduction	40
2.2 Experimental description	42
2.2.1 Methods and instrumental techniques	42
2.2.2 Synthetic procedures	42
2.3 Results and discussion	45
2.3.1 Synthesis and characterization	45
2.3.1.1 Synthesis and characterization of the 2-(arylo)pyridine ligands	45
2.3.1.2 Synthesis and characterization of the 2-(arylo)pyridine gold(III) complexes	50
2.4 Conclusions	58
2.5 References	58
<b>Chapter 3 Stability Studies of [Au(L)Cl<sub>2</sub>]Cl·xH<sub>2</sub>O complexes (where L=azpy, tazpy, 3mazpy, 4mazpy and 3mtazpy and x=1,2,3) in solution and their biological activity. The <i>in vitro</i> cytotoxic activity and the search of an structure-activity relationship</b>	61
3.1. Introduction	62
3.2. Experimental description	65
3.2.1 Methods and instrumental techniques	65
3.2.2 Stability studies	66
3.2.3 Synthetic procedure	66
3.2.4 X-ray diffraction studies	67
3.2.5 Cytotoxic studies	67
3.2. Results and discussion	68
3.3.1 Stability studies	68
A. Stability studies for Au-azpy	68
A.1 Pyrido[2,1-c][1,2,4]benzotriazin-11-ium chloride hydrate, C <sub>11</sub> H <sub>8</sub> N <sub>3</sub> Cl·H <sub>2</sub> O, pyrium chloride hydrate	69
A.2 Crystallography	71
B. Stability studies for Au-tazpy	72
C. Stability studies for Au-4mazpy	73
D. Stability studies for Au-3mtazpy	74
E. Stability studies for Au-3mazpy	76
3.3.2 <i>In vitro</i> cytotoxic activity of 2-(arylo)pyridine analogues, Au(III)-2-(arylo)pyridine compounds and the pyrium cation	83
3.3. Concluding remarks	85
3.4. References	86

# Table of Contents

	Page
<b>Chapter 4 Synthesis of new bis(arylimino)pyridine-Ru(III) compounds. Characterization and elucidation of the paramagnetic structure by means of nuclear magnetic resonance. DNA-model base studies and cytotoxic properties</b>	89
4.1 Introduction	90
4.2 Experimental section	92
4.2.1 Methods and instrumental techniques	92
4.2.2 Synthetic procedures	94
4.3 Results and discussion	96
4.3.1 Synthesis and characterization of the bis(arylimino)pyridine ligands	96
4.3.2 Synthesis and characterization of bis(arylimino)pyridine-Ru(III) compounds	101
4.3.3 DNA model base interaction	107
4.3.4 Cytotoxic activity studies	112
4.4 Conclusions	115
4.5 References	116
<b>Chapter 5 Synthesis, characterization and cytotoxic activity studies of a new family of bis(arylimino)pyridine-Ru(II) complexes. Further look in the tuning of the cytotoxic properties</b>	119
5.1 Introduction	120
5.2 Experimental section	121
5.2.1 Methods and instrumental techniques	121
5.2.2 Synthetic procedures	122
5.3 Results and discussion	126
5.3.1 Synthesis and characterization of bis(arylimino)pyridine-Ru(II) compounds	126
A. X-ray crystallography	127
B. ESI-MS	131
C. IR	131
D. Electronic absorption properties	132
E. NMR spectroscopy	134
5.3.2 Cytotoxic activity studies	138
5.4 Conclusions	139
5.5 References	140
<b>Chapter 6 Summary, General Conclusions and Further Perspectives</b>	143
6.1 Summary	144
6.2 General conclusions and further perspectives	146
6.2.1 Introduction	146
6.2.2 Au(III)-2-(arylo)pyridine compounds	146
6.2.3 Ru(II, III)-bis(arylimino)pyridine compounds	148
6.3 Final remarks	150
6.4 References	150
<b>Appendix A Novel crystallographic data of compounds developed in the research projects described in this thesis</b>	151
A.1 Introduction	152
A.2 Gold(III) Project	152
A.2.1 Introduction	152
A.2.2 Experimental section	152
A.2.3 X-ray crystallography	152

# Table of Contents

	Page
A.3 Ruthenium(II,III) Project	155
A.3.1 Introduction	155
A.3.2 Experimental section	155
A.3.3 X-ray crystallography	155
A.4 References	158
<b>Samenvatting</b>	159
<b>Curriculum Vitae</b>	163
<b>Publications</b>	164
<b>Acknowledgements</b>	165



---

# List of Abbreviations











<sup>1</sup> H NMR	Proton nuclear magnetic resonance
3mazpy	2-(phenylazo)-3-methylpyridine
3mtazpy	2-(tolylazo)-3-methylpyridine
4mazpy	2-(phenylazo)-4-methylpyridine
9EtGua	9-ethylguanine
A2780	Cisplatin sensitive human ovarian carcinoma cell line
A2780R	Cisplatin resistant human ovarian carcinoma cell line
A498	Human renal carcinoma cell line
A549	Human lung carcinoma cell line
azpy	2-(phenylazo)pyridine
bpy	2,2'-dipyridyl
CH <sub>3</sub> CN	Acetonitrile
cisplatin	<i>cis</i> -diamminedichloridoplatinum(II)
COSY	Homonuclear correlation spectroscopy
d	Doublet
dd	Doublet of doublet
DFT	Discrete Fourier transform
DMARD	Disease-modifying antirheumatic drugs
dmf	Dimethylformamide
dmsO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
EPR	Electron paramagnetic resonance spectroscopy
equiv	Equivalent
ER	Oestrogen receptor
ESI-MS	Electrospray ionization mass spectroscopy
EVSA-T	Human breast cancer cell line
GSH	Glutathione
H226	Human non-small cell lung carcinoma cell line
H <sub>4</sub> cdta	1,2-cyclohexanediaminetetraacetic acid
HeLa	Human cervical cancer cell line
HOMO	Highest occupied molecular orbital
IC <sub>50</sub>	Concentration of a compound that induces 50% of growth inhibition of cells compared to untreated cells
ICP-OES	Inductively coupled plasma optical emission spectroscopy
IGROV	Human ovarian carcinoma cell line
IR	Infrared spectroscopy
K	Kelvin degree
L1210/0	Cisplatin sensitive mouse leukaemia cell line
L1210/2	Cisplatin resistant mouse leukaemia cell line
LUMO	Lowest unoccupied molecular orbital
m	Multiplet
m/z	Mass to charge ratio
M19-MEL	Human melanoma carcinoma cell line
MCF-7	Human breast adenocarcinoma cell line
MeOH	Methanol
MHC	Major histocompatibility complex
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
NO	Nitric oxide
NSAIDs	Non-steroidal anti-inflammatory drugs
P388	Mouse leukaemia cell line
PBS	Phosphate buffered saline physiological solution
PgR	Progesterone receptor

---




phen	1,10-phenanthroline
pic	picolinate
pic-H	2-picolinic acid
Ppm	Parts per million
RF	Resistant factor, $IC_{50}$ (resistant cell line)/ $IC_{50}$ (sensitive parent cell line)
RNA	Ribonucleic acid
RT	Room temperature
s	Singlet
SAR's	Structure-activity relationships
SRB	Sulforhodamine B
t	Triplet
tazpy	2-(tolylazo)pyridine
TMS	Tetramethylsilane
tpy	2,2':6',2''-terpyridine
TxR	Selenoenzyme thioredoxin reductase
UV-Vis	Ultraviolet-Visible spectroscopy
WIDR	Human colon adenocarcinoma cell line

# Schematic representation of the compounds synthesised in this thesis

## Organic compounds







## Coordination compounds

